Depth of Response and Progression-Free Survival in CLL Patients on Ibrutinib

被引：0
|
作者：
不详
机构：
来源：
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY | 2018年 / 16卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：8 / 9
页数：2
相关论文
共 50 条
  • [1] Depth of response and progression free survival in CLL patients on ibrutinib.
    Sigmund, Audrey
    Huang, Ying
    Ruppert, Amy S.
    Ny, Fan
    Lucas, Margaret
    Chase, Weihong
    Maddocks, Kami J.
    Rogers, Kerry Anne
    Jaglowski, Samantha Mary
    Andritsos, Leslie Ann
    Awan, Farrukh Tauseef
    Grever, Michael R.
    Byrd, John C.
    Woyach, Jennifer Ann
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [2] Depth of response and progression-free survival in chronic lymphocytic leukemia patients treated with ibrutinib
    Sigmund, Audrey M.
    Huang, Ying
    Ruppert, Amy S.
    Maddocks, Kami
    Rogers, Kerry A.
    Jaglowski, Samantha
    Bhat, Seema A.
    Kittai, Adam S.
    Grever, Michael R.
    Byrd, John C.
    Woyach, Jennifer A.
    [J]. LEUKEMIA, 2022, 36 (08) : 2129 - 2131
  • [3] Depth of response and progression-free survival in chronic lymphocytic leukemia patients treated with ibrutinib
    Audrey M. Sigmund
    Ying Huang
    Amy S. Ruppert
    Kami Maddocks
    Kerry A. Rogers
    Samantha Jaglowski
    Seema A. Bhat
    Adam S. Kittai
    Michael R. Grever
    John C. Byrd
    Jennifer A. Woyach
    [J]. Leukemia, 2022, 36 : 2129 - 2131
  • [4] Measurable residual disease does not preclude prolonged progression-free survival in CLL treated with ibrutinib
    Wang, Xin Victoria
    Hanson, Curtis A.
    Tschumper, Renee C.
    Lesnick, Connie E.
    Braggio, Esteban
    Paietta, Elisabeth M.
    O'Brien, Susan
    Barrientos, Jacqueline C.
    Leis, Jose Francisco
    Zhang, Cong Christine
    Coutre, Steven E.
    Barr, Paul M.
    Cashen, Amanda F.
    Mato, Anthony R.
    Singh, Avina K.
    Mullane, Michael P.
    Erba, Harry
    Stone, Richard
    Litzow, Mark R.
    Tallman, Martin S.
    Shanafelt, Tait D.
    Kay, Neil E.
    [J]. BLOOD, 2021, 138 (26) : 2810 - 2827
  • [5] CLL: Alemtuzumab increases progression-free survival
    不详
    [J]. ONKOLOGIE, 2007, 30 (04): : 217 - 217
  • [6] Bendamustine Study Demonstrates Significant Improvement in Overall Response and Progression-Free Survival in CLL Patients
    不详
    [J]. ONCOLOGY-NEW YORK, 2009, 23 (10): : 850 - 850
  • [7] CLL: Venetoclax and Obinutuzumab prolong progression-free Survival
    Simon, Annika
    [J]. DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2019, 144 (19)
  • [8] Clinical and Genomic Factors Are Predictive of Response and Prognostic of Progression-Free Survival in Patients with Waldenstrom Macroglobulinemia Treated with Ibrutinib
    Castillo, Jorge J.
    Gustine, Joshua
    Demos, Maria
    Keezer, Andrew
    Meid, Kirsten
    Chan, Gloria G.
    Chen, Jiaji G.
    Guerrera, Maria Luisa
    Kofides, Amanda
    Munshi, Manit
    Tsakmaklis, Nicholas
    [J]. BLOOD, 2019, 134
  • [9] Zanubrutinib demonstrates superior progression-free survival vs ibrutinib for relapsed/refractory CLL/SLL: ALPINE final analysis
    Munir, Talha
    Brown, Jennifer R.
    Eichhorst, Barbara
    Hillmen, Peter
    Lamanna, Nicole
    O'Brien, Susan M.
    Tam, Constantine S.
    Qiu, Lugui
    Kazmierczak, Maciej
    Jurczak, Wojciech
    Zhou, Keshu
    Simkovic, Martin
    Mayer, Jiri
    Gillespie-Twardy, Amanda
    Ferrajoli, Alessandra
    Ganly, Peter S.
    Weinkove, Robert
    Grosicki, Sebastian
    Mital, Andrzej
    Robak, Tadeusz
    Osterborg, Anders
    Yimer, Habte A.
    Salmi, Tommi
    Wang, Megan
    Fu, Lina
    Li, Jessica
    Wu, Kenneth
    Cohen, Aileen
    Shadman, Mazyar
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2023, 201 : 14 - 15
  • [10] Improving Depth of Response With Continued Ibrutinib Therapy in CLL Patients
    不详
    [J]. CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2018, 16 (01) : 8 - 8
12345